Human plasma-derived C1-esterase inhibitor (C1–INH) is an efficacious and safe treatment for hereditary angioedema. However, thrombotic events in subjects treated with C1–INH at recommended or offlabel, high doses have been reported. In this study, we addressed the potential prothrombotic risk of C1–INH treatment in high doses using a non-clinical rabbit model. Following intravenous infusion of C1–INH to rabbits at doses up to 800 IU/kg, the exposure and the pharmacodynamic efficacy of C1–INH in rabbits were confirmed by activity measurements of C1-esterase, and coagulation factors XIa and XIIa, respectively. Potential prothrombotic effects were assessed following induction of venous and arterial thrombosis using in vivo models of venous and arterial stasis, complemented by various in vitro assays of coagulation markers. Administration of C1–INH at doses up to 800 IU/ kg did not potentiate thrombus formation during venous stasis. In contrast, inhibition of arterial occlusion was observed upon C1–INH administration when compared with isotonic saline treatment, indicating antithrombotic rather than prothrombotic activity of high dose C1–INH treatment in vivo. This was further confirmed in vitro by decreased thrombin generation, increased activated partial thromboplastin time, clotting time and clot formation time, and inhibition of platelet aggregation. No relevant changes in fibrinolysis or in the levels of thrombin-antithrombin complexes, and prothrombin fragment 1+2 were observed upon high dose C1–INH treatment. The data suggest that treatment of healthy rabbits with high doses of C1–INH could potentially inhibit coagulation and thrombus formation rather than induce a prothrombotic risk.
Keywords
Animal model -
C1-esterase inhibitor -
coagulation -
contact activation system -
thrombosis
* Equal contribution.
References
1
Bock SC,
Skriver K,
Nielsen E.
et al.
Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. Biochemistry 1986; 25: 4292-4301.
3
Caliezi C,
Wuillemin WA,
Zeerleder S.
et al.
C1-Esterase Inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev 2000; 52: 91-112.
5
Bork K.
Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor. Poster presented at the 2012 AAAAI Annual Meeting, Orlando, Florida. Allergy Asthma Clin Immunol 2010; 6: 15.
6
Bork K,
Korger G,
Kreuz W.
Review of the long-term safety of a human pasteurized C1 inhibitor concentrate. J Allergy Clin Immunol 2012; 129 (02) S AB222. Cicardi M, Zingale LC, Zanichelli A, et al. The use of plasma-derived C1 inhibitor in the treatment of hereditary angioedema. Expert Opin Pharmacother 2007; 8: 3173–3181.
10
Horstick G,
Berg O,
Heimann A.
et al.
Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: dose-related beneficial versus detrimental effects. Circulation 2001; 104: 3125-3131.
13
Ghandi PK,
Gentry WM,
Bottorff MB.
Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: Investigation from the United States Food and Drug Administration Adverse Event Reporting System Database. Pharmacotherapy 2012; 32: 902-909.
14
Relan A,
Bakhtiari K,
van Amersfoort ES.
et al.
Recombinant C1-inhibitor. Effects on coagulation and fibrinolysis in patients with hereditary angioedema. Biodrugs 2012; 26: 43-52.
16
Heydenreich N,
Nolte MW,
Göb E.
et al.
C1-inhibitor protects from brain ischemia-reperfusion injury by combined antiinflammatory and antithrombotic mechanisms. Stroke 2012; 43: 2457-2467.
17
Hagedorn I,
Schmidbauer S,
Pleines I.
et al.
Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation 2010; 121: 1510-1517.
18
Schumacher WA,
Seiler SE,
Steinbacher TE.
et al.
Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats. Eur J Pharmacol 2007; 570: 167-174.
20
Rosen ED,
Gailani D,
Castellino FJ.
FXI is essential for thrombus formation following FeCl3-induced injury of the carotid artery in the mouse. Thromb Haemost 2002; 87: 774-776.
21
Wessler S,
Ward K,
Ho C.
Studies in intravascular coagulation. III. The pathogenesis of serum-induced venous thrombosis. J Clin Invest 1955; 34: 647-651.
22
Giles AR,
Johnston M,
Hoogendoorn H.
et al.
The thrombogenicity of prothrombin complex concentrates: I. The relationship between in vitro characteristics and in vivo thrombogenicity in rabbits. Thromb Res 1980; 17: 353-366.
27
Buerke M,
Schwertz H,
Seitz W.
et al.
Novel small molecule inhibitor of C1s exerts cardioprotective effects in ischemia-reperfusion injury in rabbits. J Immunol 2001; 167: 5375-5380.
29
Chandler WL,
Levy WC,
Stratton JR.
The circulatory regulation of TPA and UPA secretion, clearance, and inhibition during exercise and during the infusion of isoproterenol and phenylephrine. Circulation 1995; 92: 2984-2994.
31
Brown NJ,
Gainer JV,
Stein CM.
et al.
Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension 1999; 33: 1431-1435.
33
Huisman LGM,
van Griensven JMT,
Kluft C.
On the role of C1-inhibitor as inhibitor of tissue-type plasminogen activator in human plasma. Thromb Hae-most 1995; 73: 466-471.
34
Sainz IM,
Pixley RA,
Colman RW.
Fifty years of research on the plasma kallikrein-kinin system: From protein structure and function to cell biology and in-vivo pathophysiology. Thromb Haemost 2007; 98: 77-83.
38
Caccia S,
Castelli R,
Maiocchi D.
et al.
Interaction of C1 inhibitor with thrombin on the endothelial surface. Blood Coagul Fibrinolysis 2011; 22: 571-575.
40
Patston PA,
Schapira M.
Regulation of C1-inhibitor function by binding to type IV collagen and heparin. Biochem Biophys Res Commun 1997; 230: 597-601.
41
Gecse A,
Kis B,
Mezei Z.
et al.
The effect of bradykinin and substance P on the arachidonate cascade of platelets. Immunopharmacology 1996; 33: 167-170.
42
Crutchley DJ,
Ryan JW,
Ryan US.
et al.
Bradykinin-induced release of prostacyclin and thromboxanes from bovine pulmonary artery endothelial cells. Studies with lower homologs and calcium antagonists. Biochim Biophys Acta 1983; 751: 99-107.
43
Schrör K.
Role of prostaglandins in the cardiovascular effects of bradykinin and angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 1992; 20: S68-73.
44
von Brühl ML,
Stark K,
Steinhart A.
et al.
Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012; 209: 819-835.
46
Mosnier LO,
Bouma BN.
Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arterioscler Thromb Vasc Biol 2006; 26: 2445-2453.
51
Wuillemin WA,
te Velthuis H,
Lubbers YT.
et al.
Potentiation of C1 inhibitor by glycosaminoglycans: dextran sulfate species are effective inhibitors of in vitro complement activation in plasma. J Immunol 1997; 159: 1953-1960.
52
Wuillemin WA,
Eldering E,
Citarella F.
et al.
Modulation of contact system pro-teases by glycosaminoglycans. Selective enhancement of the inhibition of factor XIa. J Biol Chem 1996; 271: 12913-12918.
53
Martinez-Saguer I,
Rusicke E,
Aygören-Pürsün E.
et al.
Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: a prospective study. Transfusion 2010; 50: 354-360.
